Abstract

LL37-rIb-AMP4 Hybrid Peptide as a Therapy for Systematic Infections of Acinetobacter baumannii, Pseudomonas aeruginosa, Vancomycin-resistant Enterococcus (VRE), and Methicillin-resistant Staphylococcus aureus (MRSA) cells in a mouse model.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call